Patent intelligence · US
US 9839685
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprisin…
Patent details — US 9839685
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 12, 2017
- Expiration
- Dec 7, 2037
- Claims
- 15
- CPC classes
- A61K, A61K2039/541, A61K2039/543, A61K2039/55555
Quick answer
US 9839685 (Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/541, A61K2039/543, A61K2039/55555, A61K2039/55561, A61K2039/55566
More from THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9839685?
US 9839685 (Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen) is held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9839685?
THE REGENTS OF THE UNIVERSITY OF MICHIGAN is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9839685 expire?
Our index shows an expiration date of Dec 7, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.